1 HEALTH ECONOMICS ARTICLE - BASED IN PPT AND IN THE INITIAL DRAFT. COST-EFFEXTIVENESS OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT FOR HER-2 POSITIVE BREAT CANCER.
Instituto Português de Oncologia do Porto Francisco Gentil, EPE adjudicou a Eurotrials, Consultores Cientificos, SA por 9044 €. Ajuste Direto Regime Geral…